Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... Patients with myelodysplastic syndromes (MDS), especially those with high-risk disease, other comorbidities, or of ... System (IPSS) intermediate-1 to high risk patients, in secondary acute myeloid leukemia (AML) arising from MDS, and in MDS with ...

    Research Article last updated 11/05/2012 - 9:34am.

  2. Diagnosis of myelodysplastic syndromes in cytopenic patients

    ... the bone marrow (BM), a diagnosis of cytopenia secondary to an infiltrative BM process or acute leukemia can be readily ... to establish a diagnosis of myelodysplastic syndrome (MDS). In this article, the practical approaches for establishing or excluding a ...

    Research Article last updated 11/16/2011 - 2:20pm.

  3. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy -resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to ...

    Research Article last updated 01/09/2012 - 2:17pm.

  4. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... multiple myeloma (MM) and myelodysplastic syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response ... on treatment and achieve optimal efficacy, is discussed. Secondary primary malignancies in MM and progression to acute myeloid leukemia ...

    Research Article last updated 11/16/2011 - 2:10pm.

  5. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study evaluated the time to first ... may enhance clinical benefit in patients with higher-risk MDS. Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Myelodysplastic syndromes: an update on molecular pathology.

    ... The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterised by impaired ... of involved loci is increased in high-risk disease and secondary leukaemias. A better understanding of the pathogenesis of MDS can ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) ...

    Research Review last updated 05/02/2016 - 9:32am.

  9. MEDALIST Trial

    ... very low, low, or intermediate Myelodysplastic syndrome (MDS) with ring sideroblasts (≥ 15%) who require Red blood cell (RBC) ... MDS associated with del 5q cytogenetic abnormality Secondary MDS , ie, MDS that is known to have arisen as the result of ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  10. Youmna Kfoury, PhD

    ... Myelodysplastic Syndromes (MDS) are a group of diverse and incurable pre-leukemic disorders. Even though a ... Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857. Sacchetti, B., Funari, A., ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.